JP2020510091A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020510091A5 JP2020510091A5 JP2019571788A JP2019571788A JP2020510091A5 JP 2020510091 A5 JP2020510091 A5 JP 2020510091A5 JP 2019571788 A JP2019571788 A JP 2019571788A JP 2019571788 A JP2019571788 A JP 2019571788A JP 2020510091 A5 JP2020510091 A5 JP 2020510091A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- solvate
- hydrate
- aryl
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *C(*)(*)C(*)(*)C(*)(*)*C(N(*)*)=O Chemical compound *C(*)(*)C(*)(*)C(*)(*)*C(N(*)*)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1704327.4A GB201704327D0 (en) | 2017-03-17 | 2017-03-17 | Compounds |
| GB1704327.4 | 2017-03-17 | ||
| PCT/EP2018/056663 WO2018167269A1 (en) | 2017-03-17 | 2018-03-16 | Compounds useful in the treatment or prevention of a prmt5-mediated disorder |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020510091A JP2020510091A (ja) | 2020-04-02 |
| JP2020510091A5 true JP2020510091A5 (enExample) | 2021-04-30 |
| JP7211982B2 JP7211982B2 (ja) | 2023-01-24 |
Family
ID=58688233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019571788A Active JP7211982B2 (ja) | 2017-03-17 | 2018-03-16 | Ｐｒｍｔ５媒介性障害の治療又は予防に有用な化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11485731B2 (enExample) |
| EP (1) | EP3596061B1 (enExample) |
| JP (1) | JP7211982B2 (enExample) |
| KR (1) | KR102616970B1 (enExample) |
| CN (1) | CN110650950B (enExample) |
| AU (2) | AU2018235139A1 (enExample) |
| CA (1) | CA3056724A1 (enExample) |
| GB (1) | GB201704327D0 (enExample) |
| IL (1) | IL269354B2 (enExample) |
| MX (1) | MX2019011061A (enExample) |
| SG (1) | SG11201908598PA (enExample) |
| WO (1) | WO2018167269A1 (enExample) |
| ZA (1) | ZA201906269B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10689360B1 (en) * | 2019-01-30 | 2020-06-23 | Insilico Medicine Ip Limited | TLR inhibitors |
| US11807622B2 (en) | 2019-01-30 | 2023-11-07 | Insilico Medicine Ip Limited | TLR 9 inhibitors |
| GB201905780D0 (en) * | 2019-04-25 | 2019-06-05 | La Thangue Nicholas | Cancer therapy |
| WO2020247504A1 (en) | 2019-06-06 | 2020-12-10 | Aligos Therapeutics, Inc. | Heterocyclic compounds |
| CN110950841A (zh) * | 2019-11-22 | 2020-04-03 | 济南大学 | 一类新型三唑类化合物的合成及应用 |
| WO2021126728A1 (en) * | 2019-12-17 | 2021-06-24 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| CA3174311A1 (en) * | 2020-06-02 | 2021-12-09 | Chuanwu ZHAO | 3,4-dihydroisoquinoline compound and use thereof |
| JP7620649B2 (ja) | 2020-06-10 | 2025-01-23 | アリゴス セラピューティクス インコーポレイテッド | コロナウイルス、ピコルナウイルス及びノロウイルス感染を治療するための抗ウイルス化合物 |
| WO2022002142A1 (zh) * | 2020-06-30 | 2022-01-06 | 江苏先声药业有限公司 | 四氢异喹啉类化合物及其用途 |
| EP4209485A4 (en) | 2020-09-04 | 2025-02-19 | Innovstone Therapeutics Limited | ASSOCIATES WITH ANTI-TUMOOR ACTIVITY AND USE THEREOF |
| WO2022175752A1 (en) | 2021-02-19 | 2022-08-25 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| AU2022222470A1 (en) | 2021-02-19 | 2023-09-21 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| AU2022271927B2 (en) | 2021-05-13 | 2025-07-10 | Innovstone Therapeutics Limited | Compound having anti-tumor activity and use thereof |
| GB202108383D0 (en) | 2021-06-11 | 2021-07-28 | Argonaut Therapeutics Ltd | Compounds useful in the treatment or prevention of a prmt5-mediated disorder |
| AU2022306289A1 (en) | 2021-07-09 | 2024-01-18 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| WO2023043816A1 (en) | 2021-09-17 | 2023-03-23 | Aligos Therapeutics, Inc. | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
| GB202117230D0 (en) | 2021-11-29 | 2022-01-12 | Argonaut Therapeutics Ltd | Peptide vaccine |
| EP4446317A4 (en) * | 2021-12-08 | 2025-09-17 | Cspc Zhongqi Pharmaceutical Tech Shijiazhuang Co Ltd | SALT OF 3,4-DIHYDROISOQUINOLINE COMPOUND AND ITS USE |
| CN118475569A (zh) * | 2021-12-30 | 2024-08-09 | 南京再明医药有限公司 | 四氢异喹啉类化合物的可药用盐、晶型及其用途 |
| CN118488841A (zh) * | 2022-01-06 | 2024-08-13 | 南京再明医药有限公司 | Prmt5抑制剂和抗癌治疗剂的组合 |
| GB202203588D0 (en) | 2022-03-15 | 2022-04-27 | Argonaut Therapeutics Ltd | Cancer diagnostic |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016505002A (ja) | 2012-12-21 | 2016-02-18 | エピザイム，インコーポレイティド | ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するｐｒｍｔ５阻害剤およびその使用 |
| MY199894A (en) * | 2012-12-21 | 2023-11-27 | Epizyme Inc | Prmt5 inhibitors and uses thereof |
| CA2894230A1 (en) * | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Methods of inhibiting prmt5 |
| JP2016505000A (ja) * | 2012-12-21 | 2016-02-18 | エピザイム，インコーポレイティド | Ｐｒｍｔ５阻害剤およびその使用 |
| EP3160466A4 (en) | 2014-06-25 | 2017-12-27 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| US20170198006A1 (en) * | 2014-06-25 | 2017-07-13 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| GB201415573D0 (en) | 2014-09-03 | 2014-10-15 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| US10494376B2 (en) | 2014-09-03 | 2019-12-03 | Ctxt Pty. Ltd. | Tetrahydroisoquinoline derived PRMT5-inhibitors |
-
2017
- 2017-03-17 GB GBGB1704327.4A patent/GB201704327D0/en not_active Ceased
-
2018
- 2018-03-16 MX MX2019011061A patent/MX2019011061A/es unknown
- 2018-03-16 JP JP2019571788A patent/JP7211982B2/ja active Active
- 2018-03-16 SG SG11201908598P patent/SG11201908598PA/en unknown
- 2018-03-16 CA CA3056724A patent/CA3056724A1/en active Pending
- 2018-03-16 AU AU2018235139A patent/AU2018235139A1/en not_active Abandoned
- 2018-03-16 CN CN201880032332.4A patent/CN110650950B/zh active Active
- 2018-03-16 IL IL269354A patent/IL269354B2/en unknown
- 2018-03-16 WO PCT/EP2018/056663 patent/WO2018167269A1/en not_active Ceased
- 2018-03-16 KR KR1020197030311A patent/KR102616970B1/ko active Active
- 2018-03-16 EP EP18714178.3A patent/EP3596061B1/en active Active
- 2018-03-16 US US16/494,532 patent/US11485731B2/en active Active
-
2019
- 2019-09-23 ZA ZA2019/06269A patent/ZA201906269B/en unknown
-
2022
- 2022-04-11 AU AU2022202389A patent/AU2022202389B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020510091A5 (enExample) | ||
| JP2019529490A5 (enExample) | ||
| JP2019527203A5 (enExample) | ||
| JP2018522879A5 (enExample) | ||
| JP2018536634A5 (enExample) | ||
| JP2014501766A5 (enExample) | ||
| JP2016505637A5 (enExample) | ||
| JP2016518437A5 (enExample) | ||
| JP2017523169A5 (enExample) | ||
| JP2016518328A5 (enExample) | ||
| JP2012522847A5 (enExample) | ||
| JP2019510810A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2019518766A5 (enExample) | ||
| JP2016121196A5 (enExample) | ||
| RU2012109554A (ru) | Лиганды сигма-рецепторов для предупреждения или лечения боли, вызванной химиотерапией | |
| JP2020527173A5 (enExample) | ||
| JP2016537382A5 (enExample) | ||
| RU2018102372A (ru) | Новые аминокислотные производные, способ их получения и фармацевтические композиции, содержащие их | |
| JP2019530699A5 (enExample) | ||
| JP2017508782A5 (enExample) | ||
| RU2016134751A (ru) | Соединения | |
| JP2018531218A5 (enExample) | ||
| JP2018527301A5 (ja) | アジリジン含有ｄｎａアルキル化剤 | |
| JP2020529994A5 (enExample) |